Transformative
Science

LEARN MORE

Exceptional. Together.

LEARN MORE

Total Integrity

LEARN MORE

Tireless Commitment to Patients

LEARN MORE

Exceptional Drug Discovery

Revolution Medicines is an innovative and dynamic organization of expert cellular, structural and computational biologists, biochemists, medicinal and synthetic chemists, pharmacologists, development and clinical scientists, information scientists and business executives working together to discover and develop new medicines for cancer patients.

background

We are a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive frontier targets within notorious growth and survival pathways, with particular emphasis on RAS and mTOR signaling pathways.

At Revolution Medicines, we combine our understanding of genetic drivers and adaptive resistance mechanisms in cancer with robust drug discovery and medicinal chemistry capabilities to create small molecules that target atypical binding sites on these proteins. We are using our innovation engine to develop a deep pipeline of novel targeted therapies to inhibit critical signaling nodes within the RAS and mTOR pathways.

SHP2

Our most advanced product candidate, RMC-4630, is a potent and selective inhibitor of SHP2, a central node in the RAS signaling pathway. In collaboration with our partner, Sanofi, we are evaluating RMC-4630 in a multi-cohort Phase 1/2 clinical program for a range of tumor types harboring specific oncogenic mutations.

Mutant RAS

We are also developing a portfolio of mutant-selective RAS inhibitors that we believe are the first potent, selective, cell-active inhibitors of the active, GTP-bound form of RAS, or RAS(ON). Initially, we will prioritize four mutant RAS(ON) targets - KRASG12C, KRASG13C, KRASG12D and NRASG12C.

 
A frontier oncology target is a protein that plays an important role in cancer and for which there is either: (1) no approved drug that directly inhibits it, or (2) one or more approved drugs that directly inhibit it but through a mechanism of action that doesn’t maintain suppression of the full range of its biologic contributions to cancer.

Revolution Medicines is looking for exceptionally talented individuals.

Share our passion for revolutionary science and commitment to helping oncology patients.

Join the Revolution